PUBLISHER: DelveInsight | PRODUCT CODE: 1128295
PUBLISHER: DelveInsight | PRODUCT CODE: 1128295
"EB05 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about EB05 for Acute Respiratory Distress Syndrome in seven major markets. A detailed picture of the EB05 for Acute Respiratory Distress Syndrome in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the EB05 for Acute Respiratory Distress Syndrome. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EB05 market forecast analysis for Acute Respiratory Distress Syndrome in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Acute Respiratory Distress Syndrome.
EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with ARDS. Specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling - an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and Influenza viruses.
The company received approval from Health Canada to test EB05 as a rescue therapy for critically ill patients in the Phase III part of a Phase II/III clinical study. Approval of the company's Phase III study design followed favorable Phase II results, which demonstrated compelling preliminary evidence of EB05's ability to reduce mortality in the sickest patients. Edesa has filed similar protocol amendments with the US FDA as well as other jurisdictions. In the US, the company is currently in discussions with the FDA on the design of the final Phase III protocol.
The company is also developing an EB06 monoclonal antibody in Phase II for the treatment of ARDS according to the company's pipeline. It acts by inhibiting the signaling protein CXCL10.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
EB05 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of EB05 for Acute Respiratory Distress Syndrome in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of EB05 for Acute Respiratory Distress Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions